Lumira Ventures Announces Promotion of Nikhil Thatte to Partner

June 26, 2024 / Lumira News

Lumira Ventures, a leading North American life sciences investment firm dedicated to supporting healthcare innovation and patient impact, is pleased to announce the promotion of Nikhil Thatte to the position of Partner. This promotion recognizes Nikhil’s exceptional contributions to the firm and dedication to advancing innovative healthcare solutions.

Nikhil joined Lumira Ventures in 2019 as a Principal, bringing with him extensive experience in biotech and pharmaceutical business development and investment opportunities. His keen insights, strategic vision, and unwavering commitment have been instrumental in driving the firm’s success and fostering meaningful partnerships within the industry.

“We are delighted to have Nikhil join us as a partner in the firm,” said Peter van der Velden, Managing General Partner at Lumira Ventures. “Since he joined us, he has consistently demonstrated the drive and commitment to be an exceptional investor in the life sciences sector. During the past five years, he has built and refined his skills and progressively become more intimately involved in every phase of the value creation life cycle in our sector, from sourcing to deal syndication, to active and engaged relationships with our companies, and finally to value monetization. We are proud of what he has accomplished and are very pleased to have him join the leadership team at Lumira.”

Since joining the firm, Nikhil has played a crucial role in sourcing, evaluating, and managing investments in numerous portfolio companies. Notably, he co-led Lumira’s investment in ESSA Pharma, achieving a remarkable 3x exit in under 6 months. Nikhil currently serves on the boards of Specific Biologics, Alpina Biotechnology, and BioTheryX, while also acting as a board observer for COUR Pharmaceuticals, XyloCor Therapeutics, and PIC Therapeutics. His deep understanding of industry dynamics and ability to build strong relationships have made him a trusted advisor to entrepreneurs and investors alike.

“I am proud and excited to take this step in my career with Lumira Ventures,” said Nikhil Thatte, Partner. “Lumira Ventures is founded on a long legacy of patient impact and returns, and I am looking forward to building further on this rich history. I am grateful to all of our LPs, our external partners, and my colleagues for their support, and I could not be more excited for the future of our firm and the life sciences innovation sector.”

Nikhil holds a Bachelor’s degree in Chemical Engineering from McGill University. Prior to joining Lumira Ventures, he worked as a Director of Business Development with DRI Capital and as a Consultant with ZS Associates, where he built deep domain expertise in the biotech and pharmaceutical sectors.

Lumira Ventures is committed to supporting visionary entrepreneurs and companies that are at the forefront of healthcare innovation. The promotion of Nikhil Thatte to Partner strengthens the firm’s leadership team and reinforces its dedication to advancing the next generation of life sciences companies.

For more information, please contact:

About Lumira Ventures:
Lumira Ventures is a leading North American healthcare venture capital firm with a proven 20-year track record of investing in transformative life sciences companies. As a multi-stage investor, Lumira partners with visionary entrepreneurs to build innovative companies across the entire healthcare spectrum, from early-stage therapeutics to revenue-generating medical devices. Our strategic investments have consistently yielded paradigm changing companies that deliver significant impact to patients and healthcare systems globally. To date, Lumira’s portfolio companies have brought dozens of biomedical innovations to market, improving and extending the lives of over 1 billion patients worldwide and generating more than $70 billion in cumulative revenue. Lumira Ventures remains steadfast in its commitment to delivering exceptional returns for investors while creating long-term economic value and driving meaningful societal impact.

SOURCE: Lumira Ventures

Scroll to Top